Trials / Terminated
TerminatedNCT00240214
Study Evaluating Rapamune in Patients After Kidney Transplantation
An Open Label Post Marketing Surveillance Assessment to Evaluate the Effectiveness and Safety of Rapamune in Patients After Kidney Transplantation Receiving a Rapamune Containing Regime
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to obtain data on the effectiveness and safety of Rapamune under everyday conditions
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sirolimus | Tablet, dosage is determined by trough level |
Timeline
- Start date
- 2001-04-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2005-10-17
- Last updated
- 2008-03-14
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00240214. Inclusion in this directory is not an endorsement.